{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055610","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.130751+00:00","generated_at":"2026-06-02T08:34:45.697064+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytokinetics Q1 2024 net loss $135.6M ($1.33 loss per share); cash $634M; aficamten NDA on track for Q3 2024","bullets":["Net loss of $135.6M ($1.33 per share) vs $131.3M loss ($1.38 per share) in Q1 2023.","Cash and investments $634.3M as of March 31, 2024; revenue fell to $0.8M from $4.6M.","Aficamten NDA submission planned for Q3 2024; MAA submission to EMA in Q4 2024.","Initiated enrollment in pediatric HCM trial CEDAR-HCM; MAPLE-HCM enrollment expected to complete Q3 2024.","Appointed Sung Lee as EVP, CFO effective May 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055610","json":"https://secwatch.observer/filing/0000950170-24-055610.json","markdown":"https://secwatch.observer/filing/0000950170-24-055610.md","text":"https://secwatch.observer/filing/0000950170-24-055610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/0000950170-24-055610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/cytk-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:34:45.697064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa21e0bf1d012d6eb9c80691b1f4cb3e0c919b9e","claim":"CYTOKINETICS INC reported first quarter of 2024 results: net income Net loss for the first quarter was $135.6 million, or $1.33 per share.","evidence_excerpt":"Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/0000950170-24-055610-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Net income","value":"Net loss for the first quarter was $135.6 million, or $1.33 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}